TRCT
ABCL icon

Tower Research Capital (TRC)’s AbCellera Biologics ABCL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.64K Sell
1,101
-4,630
-81% -$22.6K ﹤0.01% 4062
2026
Q1 		$20K Sell
5,731
-14,344
-71% -$51.6K ﹤0.01% 3483
2025
Q4 		$68.7K Buy
20,075
+14,901
+288% +$66.5K ﹤0.01% 2205
2025
Q3 		$26K Sell
5,174
-413
-7% -$1.82K ﹤0.01% 3071
2025
Q2 		$19.2K Buy
5,587
+1,053
+23% +$2.62K ﹤0.01% 3706
2025
Q1 		$10.1K Sell
4,534
-7,676
-63% -$22K ﹤0.01% 3677
2024
Q4 		$35.8K Sell
12,210
-3,773
-24% -$10.5K ﹤0.01% 2780
2024
Q3 		$41.6K Buy
15,983
+5,203
+48% +$14.4K ﹤0.01% 2824
2024
Q2 		$31.9K Buy
10,780
+6,406
+146% +$24.2K ﹤0.01% 3436
2024
Q1 		$19.8K Sell
4,374
-1,911
-30% -$9.75K ﹤0.01% 3008
2023
Q4 		$35.9K Sell
6,285
-2,186
-26% -$10.1K ﹤0.01% 3329
2023
Q3 		$39K Sell
8,471
-40,076
-83% -$244K ﹤0.01% 2771
2023
Q2 		$314K Buy
48,547
+43,160
+801% +$295K 0.01% 1267
2023
Q1 		$41K Sell
5,387
-8,752
-62% -$79.5K ﹤0.01% 2668
2022
Q4 		$143K Sell
14,139
-1,551
-10% -$17.9K 0.01% 1552
2022
Q3 		$155K Buy
15,690
+10
+0.1% +$110 ﹤0.01% 2164
2022
Q2 		$167K Buy
15,680
+14,123
+907% +$120K ﹤0.01% 1909
2022
Q1 		$15K Buy
1,557
+755
+94% +$7.15K ﹤0.01% 3788
2021
Q4 		$12K Sell
802
-682
-46% -$10.3K ﹤0.01% 4251
2021
Q3 		$30K Buy
1,484
+1,416
+2,082% +$25K ﹤0.01% 3369
2021
Q2 		$1K Sell
68
-3,396
-98% -$93.6K ﹤0.01% 5161
2021
Q1 		$118K Buy
3,464
+3,110
+879% +$124K ﹤0.01% 2461
2020
Q4 		$14K Buy
+354
New +$16.2K ﹤0.01% 4079

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Tower Research Capital (TRC)'s ABCL Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its AbCellera Biologics (ABCL) stake by 81% in Q2 2026, selling an estimated $22.6K and leaving 1,101 shares worth $8.64K. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

Tower Research Capital (TRC) first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $314K in Q2 2023. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Tower Research Capital (TRC) held 1,101 shares of AbCellera Biologics worth $8.64K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,630 AbCellera Biologics shares in Q2 2026, an estimated $22.6K.
  • AbCellera Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4062 holding.
  • Tower Research Capital (TRC) first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s AbCellera Biologics position peaked at $314K in Q2 2023.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.